Boston’s biotech scene may be gearing up for another high-profile IPO moment—this time led by a company betting big on the future of depression treatment. Seaport Therapeutics, a relatively young but well-funded player based in the city’s Seaport district, is preparing to enter public markets with a clear mission: push its pipeline of neuropsychiatric drugs […]
A high-stakes legal clash is unfolding in Massachusetts’ offshore wind sector, putting one of the country’s most closely watched renewable energy projects under fresh scrutiny. Vineyard Wind, the developer behind a massive wind farm off the coast of Martha’s Vineyard, has filed a lawsuit in Boston aimed at stopping its turbine supplier from exiting the
Most cancer drugs that kill tumors also damage healthy tissue. That is not a flaw in the design — it is the fundamental problem that oncology has been trying to solve for decades. And it is the problem that Stipple Bio, a Cambridge-based biotechnology company that emerged from stealth this week with a heavily oversubscribed
The optimism lasted exactly one month. In February, the Massachusetts Business Confidence Index had crossed the line separating pessimism from optimism for the first time in a year—a small but significant respite for the state’s employers after months of mounting uncertainty. In March, that relief vanished. The AIM Business Confidence Index, the longest-running barometer of
Cambridge-based Biogen announced it will acquire Apellis Pharmaceuticals, headquartered in Waltham, in an all-cash deal worth approximately $5.6 billion — or $41 per share. When Apellis stock closed on Monday, it was trading at roughly half that. By Tuesday morning, shares had more than doubled overnight. That kind of move tells you something about what
There is a pattern worth naming here. In 2024, Takeda announced a major restructuring that cut hundreds of Massachusetts jobs. In 2025, the Japanese pharmaceutical giant eliminated more Cambridge positions after shutting down its cell therapy program entirely. And this week, the company filed a WARN Act notice with the state of Massachusetts confirming that
Takeda Is Cutting 250 Jobs in Cambridge. It’s the Third Time in Two Years Read More »
Fifty million dollars is a serious amount of money for a company that started as a vaccine project in Harvard’s Innovation Lab. But then again, Ozempic is a serious amount of market — and Terrestrial Bio, the Boston-based company that just closed a $50 million Series C round, is betting it has figured out something
Something unexpected happened in the middle of 2025. While the Trump administration was cutting $27 billion from federal rental assistance programs and proposing the elimination of the Department of Housing and Urban Development as most people know it, Congress quietly did something that developers of affordable housing had been waiting years for: it made the
The Federal Tax Credit That’s Sending Boston Developers Back to the Drawing Board Read More »
Here is a number that should bother anyone who follows the startup world: in 2024, all-female founding teams received 2.1% of all venture capital deployed in the United States. Two percent. For context, that figure was 2.4% a decade ago. A full decade of “diversity initiatives,” panel discussions, and LinkedIn posts about closing the gender
Boston’s Most Successful Female Founders — And What They Actually Built Read More »
Thirty years is a long time to build something. VentureWell — the Massachusetts-based nonprofit that has funded, trained, and connected tens of thousands of science and technology entrepreneurs since 1995 — announced this week it is shutting down. The organization that helped launch student-founded companies across nearly 400 universities, that put $7 billion in investor
VentureWell Is Closing: It Took 30 Years to Build and a Stop-Work Order to End Read More »
